文献速递眼底病与葡萄膜炎

cceAAV-aflibercept-Fc-YTE基因治疗nAMD的安全性与疗效

Safety and Efficacy of cceAAV-aflibercept-Fc-YTE (F-CRG-B191): A Gene Therapy for Neovascular Age-Related Macular Degeneration.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2026-01-01

该研究开发了共价闭合端双链AAV载体cceAAV-aflibercept-Fc-YTE(F-CRG-B191),用于持续表达抗VEGF药物治疗新生血管性年龄相关性黄斑变性(nAMD)。在小鼠和非人灵长类激光诱导脉络膜新生血管(CNV)模型中,该载体较传统AAV载体显著降低IV级CNV病变发生率;首例人体给药后CNV面积持续缩小、视力改善,未观察到明显免疫反应或视网膜毒性。

要点

  • cceAAV-aflibercept-Fc-YTE在小鼠和NHP模型中较传统AAV载体显著降低IV级CNV病变发生率。
  • 首例人体给药后CNV面积持续缩小、视力改善,未见明显免疫反应或视网膜毒性。
  • 该载体是nAMD基因治疗的潜力候选,具备强效抗VEGF、持久疗效和良好安全性。

核心结论

  • cceAAV-aflibercept-Fc-YTE(F-CRG-B191)是nAMD有前景的基因治疗候选,在临床前和早期临床中显示强效抗VEGF疗效、持久治疗作用和良好安全性。

研究设计与样本

  • 研究开发了cceAAV-aflibercept-Fc-YTE,在小鼠和非人灵长类激光诱导CNV模型中评估疗效并量化IV级CNV病变发生率。
  • 开展首例人体给药(F-CRG-B191),评估解剖和功能结局及安全性,并在NHP和患者注射后监测免疫反应与视网膜毒性。

主要发现

  • 与传统表达aflibercept的AAV载体相比,cceAAV-aflibercept-Fc-YTE在小鼠和NHP模型中均显著降低IV级CNV病变发生率。
  • 人体受试者接受F-CRG-B191后CNV面积持续缩小、视力改善。
  • 临床前模型和接受治疗的患者中均未观察到明显免疫反应或视网膜毒性。

临床怎么用

  • 该载体通过持续表达抗VEGF融合蛋白有望减少nAMD反复眼内注射负担,但当前仅为临床前及首例人体早期数据,尚需更多临床研究验证。

局限性

  • 研究仅在 mice 和 NHP 模型及一名人体受试者中开展,样本量有限,长期疗效与安全性尚未确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the safety and efficacy of a novel gene therapy vector, covalently closed-end double-stranded adeno-associated virus-aflibercept-Fc-YTE (cceAAV-aflibercept-Fc-YTE; clinical trial name F-CRG-B191), designed for sustained anti-vascular endothelial growth factor (VEGF) expression in the treatment of neovascular age-related macular degeneration (nAMD). METHODS: We developed cceAAV-aflibercept-Fc-YTE. The therapeutic efficacy of cceAAV-aflibercept-Fc-YTE was evaluated in both mice and non-human primate (NHP) models with laser-induced choroidal neovascularization (CNV). The incidence of grade IV CNV lesions was quantified. A first-in-human administration of F-CRG-B191 was conducted to assess anatomical and functional outcomes, as well as safety. Immune responses and retinal toxicity were monitored in NHPs and the patient post-injection. RESULTS: Compared to conventional AAV vectors expressing aflibercept, cceAAV-aflibercept-Fc-YTE significantly reduced the incidence of grade IV CNV lesions in both mice and NHP models. In the human subject, F-CRG-B191 administration led to a sustained reduction in CNV area and improvement in visual acuity. No significant immune response or retinal toxicity was observed in either preclinical models or the treated patient. CONCLUSIONS: cceAAV-aflibercept-Fc-YTE (F-CRG-B191) is a promising gene therapy candidate for nAMD, demonstrating potent anti-VEGF efficacy, durable therapeutic effects, and favorable safety profiles in both preclinical and early clinical settings.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Shi J, Xu H, Zhao H, et al. Safety and Efficacy of cceAAV-aflibercept-Fc-YTE (F-CRG-B191): A Gene Therapy for Neovascular Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2026. PMID: 42012273. doi:10.1167/iovs.67.4.47

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。